Literature DB >> 24980932

Double arthrodesis through a medial approach for end-stage adult-acquired flatfoot.

Alan R Catanzariti1, Adebola T Adeleke2.   

Abstract

Triple arthrodesis has traditionally been the procedure of choice for end-stage adult-acquired flatfoot. The results have been universally good, and it has proven to be dependable and predictable. Nonetheless, complications have been reported following triple arthrodesis in certain patients. Selective arthrodesis of the talonavicular joint and subtalar joint through a single medial approach has been developed as an alternative. The authors especially prefer this procedure with severe transverse plane deformity and often choose this approach as an alternative to triple arthrodesis in high-risk patients, including those patients with diabetes mellitus, rheumatoid arthritis, long-term steroid use, and the elderly.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Double arthrodesis; End-stage adult-acquired flatfoot; Medial approach

Mesh:

Year:  2014        PMID: 24980932     DOI: 10.1016/j.cpm.2014.04.001

Source DB:  PubMed          Journal:  Clin Podiatr Med Surg        ISSN: 0891-8422            Impact factor:   1.231


  3 in total

Review 1.  [Joint-preserving surgical correction of advanced flexible planovalgus deformity of the adult foot].

Authors:  Jörn Dohle
Journal:  Orthopade       Date:  2020-11       Impact factor: 1.087

2.  A mid-term follow-up of Koutsogiannis' osteotomy in adult-acquired flatfoot stage II and "early stage III".

Authors:  Camilla Arvinius; Elena Manrique; Antonio Urda; Zulema Cardoso; Jose Enrique Galeote; Fernando Marco
Journal:  SICOT J       Date:  2017-03-17

3.  Adult-Acquired Flatfoot Deformity: Combined Talonavicular Arthrodesis and Calcaneal Displacement Osteotomy versus Double Arthrodesis.

Authors:  Sebastian Fischer; Julia Oepping; Jan Altmeppen; Yves Gramlich; Oliver Neun; Sebastian Manegold; Reinhard Hoffmann
Journal:  J Clin Med       Date:  2022-02-05       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.